Introduction: Little is known about effects of smoking cessation on alcohol consumption. Varenicline reduces enjoyment of smoking and cigarette consumption and may also reduce enjoyment and consumption of alcohol. We conducted the first prospective examination of the effects of stopping smoking on alcohol enjoyment and consumption and compared clients using varenicline and nicotine replacement treatment (NRT). Methods: Audit of records from clients undergoing routine smoking cessation treatment in three stop-smoking services in London, United Kingdom. The sample comprised smokers who consume alcohol and underwent smoking cessation treatment with either varenicline (N = 230) or NRT (N = 62). Alcohol enjoyment and consumption were reported before and on the target quit day (TQD) and 1 and 4 weeks post-TQD. Results: Participants reduced their alcohol consumption in week 1 of their quit attempt (15.0-12.7 units per/week, p = .001).In heavy drinkers, the change remained significant at 4 weeks (32.2-24.8 units per/week, p = .004). The type of medication used had no significant impact on the change. Smokers treated with varenicline versus NRT were more likely to report reduced enjoyment of alcohol on TQD (20% vs. 10%, respectively, p < .001) and at 4 weeks post-TQD (20% vs. 6%, respectively, p = .014). Results were similar for abstainers and those who did not manage to stop smoking. Conclusion: Making a stop-smoking attempt is accompanied by a reduction in drinking. The finding has implications for policies concerned with effects of stopping smoking on alcohol use. Varenicline may affect enjoyment of drinking, but its potential to alter drinking behavior is small. Implications: The finding that smokers making a quit attempt reduce their alcohol consumption has practical implications for treatment providers who are concerned about the possible effects of smoking cessation on alcohol drinking. Although varenicline may reduce alcohol enjoyment compared to NRT, it does not appear to have a significant impact on alcohol consumption.
Introduction
Smoking and alcohol consumption have a close relationship. 1 Heavy drinkers have typically high tobacco dependence and low quitting success, 2 although past history of drinking may have no effect on smoking cessation outcomes. 3 Smoking cessation in people undergoing treatment for alcohol dependence can aid sobriety rather than hinder it, 4 ,5 but offering treatment is not the same as actually stopping smoking, 6 so the effects of actual smoking abstinence, as opposed to treatment offer, are not well mapped. A randomized trial studied effects of adding alcohol counseling to standard smoking cessation treatment of heavy drinkers. The intervention led to reduced drinking and did not impair smoking cessation. 7 Surprisingly, effects of stopping smoking on alcohol consumption are not well known in the general population of smokers. The self-medication and reward-seeking hypotheses would suggest that removing one source of relief or gratification may increase reliance on the use of the remaining sources, 8 but the hypothesis has not been extensively tested in this field so far. In the only study that monitored alcohol use in smokers attempting to quit that we are aware of, there was no change in drinking in successful abstainers. 9 A moderate effect of quitting smoking on alcohol consumption, however, could have been missed because the sample had overall very low drink consumption at baseline (0.2 drinks per day, SD = 0.7) and must have included a proportion of smokers who did not drink at all. A recent cross-sectional survey reported that smokers trying to quit consume less alcohol than those who do not, but it is not clear whether these differences predated the quit attempt. 10 Prospective follow-up data are needed to clarify whether stopping smoking changes drinking behavior in the general population of smokers and in what direction.
Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor, reduces cigarette withdrawal and craving and facilitates smoking cessation. 11 There is also emerging evidence that its use while smoking ad libitum reduces cigarette use as well as smoking enjoyment. 12 Several preclinical and clinical studies have suggested that the drug may have similar effects on use and enjoyment of alcohol, although the results were not clear cut. Varenicline reduced ethanol consumption in rats but only at very high doses of at least 1 mg/kg. [13] [14] [15] In rats bred for ethanol drinking, the effect disappeared after about 1 week of dosing. 16 Three small placebo-controlled studies in smokers consuming >7 units of alcohol per week in women and >14 units in men also reported some effects including reduced alcohol intake (but no effect on craving or on number of dry days) 17 ; less alcohol intake after a priming dose 18 ; and fewer heavy drinking days. 19 A larger study including 200 alcoholics who wanted to stop drinking found a reduction in the number of heavy drinking days and in mean drinks per day (6 vs. 7 in varenicline and placebo arms, respectively) but no effect on abstinence. 20 Nicotine replacement treatment (NRT) targets the same acetylcholine receptors as smoking, and there is little a priori reason to expect that it could have effects on drinking different from effects of smoking. NRT users typically under dose compared to smoking, and so any effects could be ascribed to nicotine reduction. Several studies however addressed this issue. The nicotine patch was found to increase alcohol consumption in men, and decrease consumption in women, following a priming drink 21 ; and in another study, it delayed the initiation of drinking. 22 A large international survey reported that NRT users were more likely to consume alcohol once a month or more compared to those using varenicline and to those who had used no stop-smoking medications. 23 Varenicline use was associated with a reduced likelihood of consuming alcohol once a month or more compared to no medication. However, neither NRT nor varenicline use were associated with more frequent drinking (i.e. once a week or more). The findings are however difficult to interpret as the length of medication use and timing of use was unknown, meaning that many respondents were likely not currently using their medications. Additionally, around 20% of respondents who did not drink at all were included in the sample.
We conducted an audit of stop-smoking service records to examine (1) changes in alcohol consumption and enjoyment in smokers undergoing routine smoking cessation treatment and (2) differences in these variables between smokers using NRT and smokers using varenicline.
Methods

Design and Sample
Clients attending routine stop-smoking services in the London boroughs of City, Hackney, and Tower Hamlets between January 2009 and January 2013 provided data on their drinking at baseline (prior to their target quit date [TQD] ) and at 1 and 4 weeks post-TQD. We compared changes in alcohol consumption and enjoyment in clients using varenicline and clients using NRT; and clients within the varenicline group who did and did not show a strong reaction to the drug by spontaneously reducing their cigarette consumption by at least 50% during the prequit period (varenicline "responders"). We also examined whether smoking status (smoker vs. abstainer) and drinker type (normal or heavy) moderated any effects.
Smoking Cessation Treatment
Clients received standard National Health Service Specialist Stop Smoking Service treatment over seven weekly sessions either in groups or individually. 24, 25 The treatment combines stop-smoking medications and behavioral support. The TQD was at session 3. At the first session, 3 weeks before TQD, medication options were presented, and patients selected their preferred medication from among varenicline, different types of NRT and their combinations, or bupropion. Bupropion was rarely used, and clients who opted for it are not included in the analysis. NRT options typically included a combination of nicotine patch with a faster acting product (e.g., nicotine gum, lozenge, mouth spray, nasal spray, or inhalator). NRT use began on the TQD. Varenicline use began 1-2 weeks prior to the TQD per labeling. The uptitration schedule of varenicline included days 1-3: 0.5 mg/day; days 3-7: 0.5mg/BD; day 8 onward: 1 mg/ BD, per labeling. All clients were encouraged to smoke ad libitum until their TQD. Both medications were provided for up to 12 weeks.
Measures
Baseline data included demographic information and smoking and drinking history. At baseline, TQD, and at 1 and 4 week post-TQD, self-reported alcohol consumption (number of units per week) was recorded: "How many units of alcohol do you drink during a typical week (baseline)/have drunk in the last week (follow-ups) (one unit = glass of wine / half pint of beer / single spirit)?"Clients also rated their enjoyment of alcohol on the TQD, week 1, and week 4 post-TQD by answering the question: "Compared to how you felt about alcohol before coming to the smokers clinic, how did you found it during the last week?" The six response options included much more enjoyable; slightly more enjoyable; same as before; slightly less enjoyable; much less enjoyable; and did not drink any alcohol.
Smoking status was recorded at each post-TQD visit. Clients were classified as abstainers if their self-reported abstinence from smoking was verified by a carbon monoxide (CO) concentration of <10 ppm (CO cutoff point used by the UK SSS) in expired air.
Analyses
Repeated measures analyses of variance were used to assess the main effect of time on alcohol consumption and to compare NRT and varenicline users in changes in consumption of alcohol from baseline at different time points, including changes between the baseline session and TQD, that is, a period where both groups smoked ad libitum, and only varenicline users were using their medication. Analyses for each post-TQD data point were conducted separately for the whole sample. We also explored whether smoking status (smoker vs. abstainer) and drinker type (normal or heavy) moderated any effects of time and/or medication on alcohol consumption and enjoyment.
Responses to the enjoyment of alcohol question were categorized into decreased enjoyment ("slightly less enjoyable" or "much less enjoyable"), no change ("same as before"), or increased enjoyment ("slightly more enjoyable" or "much more enjoyable") and analyzed via chi-square tests. Clients who reported not drinking alcohol were removed from the analyses.
Finally, we examined varenicline effects on alcohol use and enjoyment in "varenicline responders." Varenicline is used for at least a week prior to TQD, and we have previously documented that a reduction in ad libitum cigarette consumption of at least 50% during this prequit period predicts successful quitting and is likely to index a strong reaction to the drug. 12 We compared these clients with those whose cigarette consumption during the prequit period did not reduce to this extent. All statistical tests were two-tailed.
Results
Participant Characteristics
During the audit period, 570 clients used one of the two target medications. Clients with missing baseline data on alcohol consumption (n = 77) and enjoyment of alcohol (n = 120), and clients who reported not drinking alcohol at all (N = 81) were removed from analyses. A total of 292 clients (62 using NRT and 230 using varenicline) comprised the final sample. Clients retained in the sample had higher rates of employment (74% vs. 64%, p = .042) and higher CO readings at baseline (21 vs. 18 ppm, p = .028) compared to those who were excluded.
Demographic characteristics of the sample are shown in Table 1 . There were no significant differences between varenicline and NRT users. Table 2 shows changes in alcohol consumption at each time point. Clients reduced their alcohol intake significantly (by about 15%) between baseline and 1 week post-TQD. At baseline, the mean units consumed per week was 15.0 compared to 12.7 at 1 week post-TQD. The difference was reduced to nonsignificant levels at 4 weeks (14.1 units at baseline vs. 12.8 units at 4 weeks). The changes happened independent of medication type.
Alcohol Consumption
We
Smoking status did not affect changes in alcohol consumption: There were no significant interactions between Medication, Time, and Smoking status at both 1 and 4 weeks post-TQD (p = .797 and p = .976, respectively).
However, drinker type moderated changes in alcohol consumption over time: "Heavier" drinkers reduced their drinking more than "normal" drinkers from baseline to TQD (from 32 units to 28 for heavy drinkers vs. no change in normal drinkers; p < .001); from baseline to 1 week post-TQD (from 32 units to 26 for heavy drinkers vs. 9 units to 8 units for normal drinkers; p < .001); and from baseline to 4 weeks post-TQD (from 32 units to 25 for heavy drinkers vs. 9 units to 10 for normal drinkers; p < .001). The details of changes in alcohol intake in the subsample of heavy drinkers are presented in Table 3 . Table 4 shows the effects of time and medication on enjoyment of alcohol. The majority of clients reported no changes in their enjoyment of alcohol across the three time points: At TQD, 77% reported no changes, 18% a reduction, and 5% an increase; at 1-week post-TQD, 71% reported no change, 19% a reduction, and 9% reported an increase; at 4 weeks post-TQD, 69% now reported no changes, with 17% reporting a reduction and 14% reporting an increase. Varenicline users were more likely than NRT users to report reduced enjoyment of alcohol at TQD (20% vs. 10%, respectively, p < .001) and at 4 weeks post-TQD (20% vs. 6%, respectively, p = .014) but not at 1-week post-TQD. Similar proportions of varenicline and NRT users reported an increase in enjoyment of alcohol across the three time points. The proportion of clients enjoying their alcohol less, more, or the same in the two medication groups did not vary by smoking status at either 1 or 4 weeks post-TQD (p = .847 and p = .392, respectively). Drinker type (normal vs. heavy) also did not moderate any effects of medication type on alcohol enjoyment at any time point (all p's > .05).
Enjoyment of Alcohol
Effects in "Varenicline Responders"
Among varenicline users for whom data on cigarette consumption were available (n = 263), 61 (23%) reduced their cigarette consumption by 50% or more during the prequit period and were classified as "varenicline responders." Of these, 50 clients provided data on at least 1 follow-up point.
Alcohol consumption reduced significantly from baseline to 1 week post-TQD in responders (from 12.2 to 10.2 units, p < .01) and nonresponders (from 17.0 to 14.5 units, p < .01), with no difference between the two groups (p = .065). There were no further reductions in either group at any later time point.
The early response to varenicline did not have a significant effect on enjoyment of alcohol at any time point.
Effects of Medication and Alcohol Consumption on Smoking Abstinence Rates
Varenicline users had higher abstinence rates than NRT users at 4 weeks post-TQD (63.8% vs. 50%, respectively, p = .016). Chisquare analyses showed that baseline alcohol consumption (normal vs. heavy) had no effect on abstinence rates at 4 weeks.
Discussion
Smokers embarking on a quit attempt reduced their alcohol intake after the TQD. The effect was moderated by drinker type, in that heavier drinkers had a greater reduction. There was no moderating effect of smoking status. This is consistent with a previous study of heavy drinkers, where by those who were abstinent at follow-up were consuming similar levels of alcohol than those who were still smoking. 7 The finding that making a quit attempt generates an acute reduction in drinking is novel and somewhat unexpected. It contradicts the popular notion that people deprived of cigarettes will compensate by increasing their use of alcohol and more generally that removing one source of reinforcement will increase the value and use of others. A recent review on the possible impact of very low nicotine content cigarettes (VLNC) on alcohol consumption 26 concluded that VLNC would likely not lead to compensatory alcohol use in the long term because of reduced exposure to nicotine smoking cues associated with alcohol use (see also McKee and Weinberger 27 ) but that Abbreviation: TQD = target quit day; NRT= nicotine replacement treatment. *p < .001, **p = .014.
short-term increases may be evident as individuals try to cope with nicotine withdrawal symptoms. The only previous study of changes in drinking that we are aware of 9 found no mean postquit change, but the sample included people who did not drink alcohol at all and the baseline alcohol consumption (0.2 units per day) was so low that the study had limited power to detect any further decrease. Our approach differed in that we excluded nondrinkers, and in this sample, the mean baseline alcohol consumption was over 2 units per day.
One possible explanation of our finding is that clients were reducing their drinking to avoid smoking relapse. 10 The relationship between alcohol and smoking relapse is well documented, [28] [29] [30] and smokers, particularly those who are heavy drinkers, are advised to restrict alcohol consumption during a stop-smoking attempt. 28, 31, 32 Smokers using varenicline for 1-2 weeks prior to TQD were more likely to report reduced enjoyment of drinking on the TQD than smokers who were not medicated during that period and who were about to start using NRT. The effect disappeared 1 week later but emerged again at 4 weeks post-TQD. Medication type however had no effect on alcohol consumption. The results were similar in clients who did and those who did not manage to abstain from smoking. In the subgroup of heavy drinkers, varenicline had no effect on enjoyment of alcohol.
The early reaction to the varenicline, indexed by a spontaneous reduction in cigarette consumption of at least 50%, was not related to alcohol enjoyment or consumption.
The study had several limitations. Medication type was selfselected. Clients opting for varenicline and those opting for NRT did not differ in alcohol consumption or any other characteristics assessed at baseline, but there may have been differences in characteristics we did not monitor. The overall sample size was relatively large, but it became limited for some analyses of specific subsamples. Data on medication adherence were not captured. Self-reported alcohol consumption was not verified biochemically, but there was no obvious reason for clients to misreport changes in their drinking, and if there was such a tendency, it was unlikely to be different for the two medication groups. The varenicline group used their medication during the prequit period while NRT use only started on TQD. It is thus possible that self-reported effects on enjoyment of drinking on the TQD could have been influenced by expectations. This however would be less likely to cause the difference observed at 4 weeks post-TQD.
Despite these caveats and the fact that some of the trends we observed could become significant in larger samples, it would appear that in smokers undergoing stop-smoking treatment, varenicline and NRT did not differentially impact drinking. Varenicline had no effect on drinking compared to no medication during the prequit period either. Together, these findings suggest that any effects of varenicline on alcohol consumption are likely to be limited. Our findings appear to contradict previous trials [17] [18] [19] which reported some evidence of varenicline reducing alcohol consumption in patients undergoing treatment for alcohol dependence. It remains possible that varenicline has different effects in alcoholics using the medication to stop drinking. 20 The effect of varenicline on alcohol enjoyment is interesting and if confirmed by other studies, it would have theoretical implications. The changes in alcohol enjoyment in the control group (NRT users) who used no medication prior to the TQD were random, with 10% reporting an increase, 10% a decrease, and 80% noticing no change in enjoyment of alcohol. After TQD, ratings in the NRT group fluctuated, with no clear direction. In contrast to this, in the varenicline group, 20% reported reduced enjoyment of alcohol throughout the four weeks of follow-up. The difference between the two groups was not robust (it disappeared at week 1 post-TQD) and may have been a chance finding, but if genuine, it would suggest that in a subset of people, enjoyment of smoking and enjoyment of alcohol may be mediated by the same processes that are affected by neural targets altered by varenicline, such as α4β2nicotinic receptors.
The study generated another finding that is of clinical relevance. In this sample of clients undergoing routine treatment, varenicline was significantly more effective than NRT for smoking cessation. Clients self-selected their medications, and this result needs to be interpreted with caution, but it tallies with other observational and experimental data. 33, 34 In conclusion, making a stop-smoking attempt is accompanied by a reduction in alcohol consumption. The finding has practical implications for treatment providers concerned about adverse effects smoking cessation may have on alcohol consumption and for relevant policies. Varenicline may affect enjoyment of drinking in some users, but in smokers undergoing stop-smoking treatment, its potential to alter drinking behavior is likely to be small.
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